First Hawaiian Bank Acquires 3,350 Shares of USANA Health Sciences, Inc. (NYSE:USNA)

First Hawaiian Bank raised its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 36.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,439 shares of the company’s stock after buying an additional 3,350 shares during the period. First Hawaiian Bank owned about 0.07% of USANA Health Sciences worth $563,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in USNA. Quest Partners LLC acquired a new position in USANA Health Sciences in the 4th quarter valued at about $66,000. CWM LLC grew its holdings in USANA Health Sciences by 49.6% during the 4th quarter. CWM LLC now owns 1,267 shares of the company’s stock worth $68,000 after acquiring an additional 420 shares in the last quarter. BOKF NA increased its holdings in shares of USANA Health Sciences by 274.5% in the 1st quarter. BOKF NA now owns 2,771 shares of the company’s stock valued at $133,000 after acquiring an additional 2,031 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of USANA Health Sciences during the 4th quarter worth approximately $266,000. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of USANA Health Sciences by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock valued at $284,000 after purchasing an additional 494 shares during the period. Institutional investors own 54.25% of the company’s stock.

Insider Buying and Selling at USANA Health Sciences

In related news, CFO G Doug Iiekking sold 5,198 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $44.76, for a total transaction of $232,662.48. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, insider Paul A. Jones sold 2,714 shares of the company’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $48.66, for a total transaction of $132,063.24. Following the completion of the sale, the insider now owns 6,266 shares in the company, valued at $304,903.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO G Doug Iiekking sold 5,198 shares of the firm’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $44.76, for a total value of $232,662.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,800 shares of company stock worth $1,323,820. Insiders own 0.33% of the company’s stock.

USANA Health Sciences Stock Performance

Shares of USNA stock traded down $3.54 during trading on Monday, hitting $39.28. 150,388 shares of the company were exchanged, compared to its average volume of 80,504. The firm has a market capitalization of $748.28 million, a price-to-earnings ratio of 12.27, a P/E/G ratio of 1.43 and a beta of 0.90. The business’s 50-day simple moving average is $45.54 and its 200 day simple moving average is $46.70. USANA Health Sciences, Inc. has a twelve month low of $38.67 and a twelve month high of $66.69.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, July 23rd. The company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.11). The firm had revenue of $212.87 million during the quarter, compared to the consensus estimate of $218.64 million. USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. During the same period last year, the business earned $0.89 earnings per share. On average, equities analysts forecast that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. DA Davidson cut their target price on USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, July 25th. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.